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Differential Proteomic Analysis of 
Human Saliva using Tandem Mass 
Tags Quantification for Gastric 
Cancer Detection
Hua Xiao1, Yan Zhang2, Yong Kim3, Sung Kim4, Jae Joon Kim5, Kyoung Mee Kim6, 
Janice Yoshizawa3, Liu-Yin Fan1, Cheng-Xi Cao1 & David T. W. Wong3
Novel biomarkers and non-invasive diagnostic methods are urgently needed for the screening of 
gastric cancer to reduce its high mortality. We employed quantitative proteomics approach to develop 
discriminatory biomarker signatures from human saliva for the detection of gastric cancer. Salivary 
proteins were analyzed and compared between gastric cancer patients and matched control subjects by 
using tandem mass tags (TMT) technology. More than 500 proteins were identified with quantification, 
and 48 of them showed significant difference expression (p < 0.05) between normal controls and gastric 
cancer patients, including 7 up-regulated proteins and 41 down-regulated proteins. Five proteins 
were selected for initial verification by ELISA and three were successfully verified, namely cystatin B 
(CSTB), triosephosphate isomerase (TPI1), and deleted in malignant brain tumors 1 protein (DMBT1). 
All three proteins could differentiate gastric cancer patients from normal control subjects, dramatically 
(p < 0.05). The combination of these three biomarkers could reach 85% sensitivity and 80% specificity 
for the detection of gastric cancer with accuracy of 0.93. This study provides the proof of concept of 
salivary biomarkers for the non-invasive detection of gastric cancer. It is highly encouraging to turn 
these biomarkers into an applicable clinical test after large scale validation.
Although the incidence and mortality have fallen dramatically over the past several decades, gastric cancer is still 
a major public health issue as the fourth most common cancer and the second leading cause of cancer related 
death worldwide1,2. Approximately 880,000 people succumb to this malignancy each year on the earth. Radical 
surgery is the only potential curative method for the localized disease. One of the main reasons for the high 
mortality is the delay in diagnosis due to the fact that early cancers are typically asymptomatic or causes only 
nonspecific symptoms3. About 90% of gastric cancers are adenocarcinomas. Non-Hodgkin’s lymphomas and lei-
omyosarcomas make up most of the remaining 10%4. Helicobacter pylori (H. pylori) infection is the strongest 
known risk factor for malignancies that arise within the stomach, and epidemiological studies have determined 
that the attributable risk for gastric cancer conferred by H. pylori is about 75%5–8. Usually the 5 year survival 
rates for gastric cancer are less than 30% in many countries, although it has been significantly improved in some 
Asian countries by up to 50% because of the early detection programs9. The corresponding 5 year survival rates 
for stage I and II patients are 67%, compared to 31% and 8% in stage III and IV patients, respectively10. Therefore, 
novel biomarkers and non-invasive diagnostic methods are urgently needed for the screening of gastric cancer to 
reduce the high mortality.
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The detection of gastric cancer in the early stages is vitally important in ensuring an excellent prognosis8. 
However, as with other cancers, the challenges in early detection lie in the reality of non-specific symptoms 
and invasive physical procedures11. The symptoms of early stage cancer may be indistinguishable from those of 
benign dyspepsia, while the presence of alarm symptoms may imply an advanced and often inoperable disease. 
Dysphagia, weight loss, and a palpable abdominal mass appear to be major independent prognostic factors for 
gastric cancer. However, gastro-intestinal bleeding, vomiting and duration of symptoms, do not seem to have a 
relevant prognostic impact on the survival of gastric cancer3.
Biomarker discovery for gastric cancer has mainly focused on tissue12,13, blood14,15 or gastric juice samples16 
for the identification of protein17, microRNA18, long non-coding RNA19, and DNA20 candidates. For example, 
serum TIMP-115 has been identified as prognostic biomarkers for gastric cancer. Clinical proteomic study has 
shown that IPO-38 protein is a promising biomarker both for diagnosis and for predicting prognosis of gastric 
cancer17. Besides, biomarker discovery has been carried out with the treatment of EGFR binding monoclonal 
antibody in advanced gastric cancer21,22. However, there are few reliable serum biomarkers for the diagnosis of 
gastric cancer so far. The available biomarkers of CEA, CA19-9 and CA72-4 are not sufficiently sensitive and 
specific for the detection of gastric cancer17.
Proteomics is a powerful approach for biomedical research. Mapping proteomes from tissues, cells, and 
organisms is being used to discover new disease biomarkers for clinical and diagnostic applications23. Cancer 
proteomics has been extensively used for the discovery of diagnostic biomarker for gastric cancer24,25. Different 
quantitative proteomics have been widely used for biomarker discovery in different types of samples, including 
surface-enhanced laser desorption/ionization26, two-dimensional gel electrophoresis-mass spectrometry27,28, and 
isobaric tag for relative and absolute quantitation (iTRAQ)29. Proteomics using mass spectrometry with Tandem 
Mass Tags (TMT) is a reliable technology for quantitative proteome analysis30. Each isobaric tagging reagent 
within a set has the same precursor mass and is composed of an amine-reactive NHS-ester group, a spacer arm 
and an MS/MS reporter. For each sample, a unique reporter mass results in the MS/MS spectrum (i.e., m/z 126–
131 for TMT-6plex Isobaric Label Reagents). These reporter product ions are used to report relative protein 
expression levels31,32,33.
Endoscopy with biopsy sampling is the gold standard used in gastric cancer diagnosis34. However, the invasive 
and relentless character of this procedure makes it less suitable for fast screening35. Human saliva is a biological 
fluid with enormous diagnostic potentials. Because saliva can be non-invasively collected, it provides an attrac-
tive alternative approach for cancer diagnosis. Saliva harbors a wide array of components, especially proteins36,37, 
which can be very informative for the detection of oral diseases (e.g. oral cancer38 and Sjogren’s Syndrome39) and 
systemic diseases (e.g. breast cancer40 and lung cancer41). More specifically, saliva protein finger print has been 
preliminary analyzed for the early diagnosis of gastric cancer42. Besides, gram-negative bacterium Helicobacter 
pylori could secrete enzyme urease and convert urea into carbon dioxide and ammonia. Optoelectronic sensors 
have been developed to detect clinically relevant levels of carbon dioxide and ammonia in saliva that can poten-
tially be used for early diagnosis of gastric cancer35.
In this study, we hypothesized that gastric cancer related proteins exist in human saliva, which could be clin-
ically used to discriminate gastric cancer patients from healthy control subjects. Human saliva samples were 
collected from gastric cancer patients and matched healthy control subjects. Salivary proteins were analysed and 
compared between the two groups by using TMT technology for proteomic biomarker identification and quan-
tification. Candidate proteomic biomarkers were selected and further verified by immunoassay. Their utility for 
the detection of gastric cancer has been evaluated. With the discovery and pre-validation of discriminatory pro-
teomic markers from saliva, gastric cancer will be non-invasively detected with high specificity and sensitivity.
Results
The strategy for salivary proteomic biomarker discovery. The study design is briefly shown in 
Fig. 1A. The 40 gastric cancer saliva samples were collected from patients who have been diagnosed as gastric 
cancer by using biopsy at the Samsung Medical Center (Seoul, Korea); most of them were at their early stages, as a 
result of the National Cancer Screening Program for gastric cancer in Korea43. The saliva samples from 40 healthy 
control subjects were collected as controls by matching their age-, sex-, and ethnicity- with the cancer group. 
Their smoking and drinking history were matched generally by whether they are current or former smokers and 
their duration and intensity. Their H. pylori infection and intestinal metaplasia status was included. Patient demo-
graphics and clinical profiles are present in Table 1.
Amylase depletion. Alpha amylase is the most abundant protein in human saliva, accounts for about 
50–60% of the total protein amount, which hurdled the detection and quantification of low abundant proteins. 
Depletion of these interfering proteins prior to definitive analyses should improve the resolution and sensitivity 
of salivary proteome analysis36. The one-dimensional SDS-polyacrylamide gel electrophoresis (1D SDS-PAGE) 
of salivary protein profiling before and after amylase depletion is shown in Fig. 2A. Obviously, the dominant 
band in the saliva without treatment disappeared after flow through the starch column. Figure 2B shows the 
two-dimensional difference gel electrophoresis (2D-DIGE) of two random saliva samples before and after amyl-
ase depletion, the dominant spots labeled in circle in Fig. 2B (a) significantly decreased when compare to that 
with amylase depletion in Fig. 2B (b).
Cation exchange peptide fraction and peptides preparation. After amylase depletion, saliva pro-
teins in each sample were reduced, alkylated and then digested by trypsin. According to the assignment in Fig. 1B, 
each sample in each group was labeled with corresponding tags of TMT-6plex. Combined peptides in group I and 
group II were fractionated by cation exchange chromatography column into 12 fractions, respectively, as shown 
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in Supplementary Figure S2. All the fractions were dried under vacuum and were rehydrated in mobile phase B 
for further analysis.
Identification of differentially expressed proteins in saliva. Each fraction was loaded to liquid 
chromatography tandem mass spectrometry (LC-MS/MS) for protein identification and quantification. The 
raw data generated from the 12 fractions in each group was combined for protein database search and analysed 
in Proteome Discoverer with designed TMT workflow. Briefly, collision-induced dissociation (CID) spectrum 
was selected from total spectrum and used for protein identification. SEQUEST was interfaced with Proteome 
Discoverer for protein database search against IPI human database. Higher energy collisional dissociation (HCD) 
spectrum was extracted from the total spectrum and specifically used for reporter ion quantification. In this 
study, a global internal standard (GIS) was made and added to each group, specifically the GIS was labelled by 
TMT m/z at 126.1 in both groups. All the reading of other samples was compared with this GIS, which made the 
signal of all 10 samples in group I and group II comparable.
The database search results for group I and group II were exported to Microsoft Excel software, including the 
protein identification and quantification intensity ratios. In total, 519 proteins were identified from all the sam-
ples. The quantification data of cancer group and control group was extracted from the corresponding database 
search results. The distribution of individual proteins in cancer group and control group were systematically com-
pared. 48 proteins showed significant difference (p < 0.05) between cancer group and control group (Table 2). For 
high throughput biomarker verification and validation, only these gastric cancer related candidates with available 
ELISA kits were selected for further evaluation.
Figure 1. Study design (A) and experimental design (B) for proteomic biomarker development in human 
saliva.
www.nature.com/scientificreports/
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Among these identified 519 proteins, their fold change ranged from 0.48 to 7.9 (Fig. 3A). 292 proteins were 
quantified with fold change in the range of 0.8 and 1.2. 80 proteins were up-regulated in the cancer group with 
fold change greater than 1.2. Meanwhile, 147 proteins were down-regulated in the cancer group (Fig. 3B) with 
fold change less than 0.8.
TMT based protein identification and quantification. The TMT quantification data of 6 can-
didates biomarker with p < 0.05, including CSTB, TPI1, DMBT1, Calmodulin-like protein 3 (CALML3), 
Immunoglobulin heavy chain (IGH), Interleukin-1 receptor antagonist (ILIRA), are shown in Fig. 4. The repre-
sentative MS/MS spectrum of CSTB are shown in Fig. 5. Figure 5A,B are the CID spectrum and HCD spectrum 
for one peptide of CSTB, respectively. The rectangle labeled peaks in Fig. 5B are the TMT for quantification of this 
peptide. The reporter ion spectra for two different peptides of CSTB from group I, as shown in Fig. 5C,D, are very 
consistent, which represented the systematic down regulation of CSTB in cancer patients.
Gene ontology analysis by PANTHER. Protein classification was finished by Panther Classification 
System based on their molecular function, related biological process, cellular component, protein class and 
related pathway. The Gene Oncology protein class analysis and pathway analysis of these proteins are shown in 
Fig. 6A,B, respectively.
Candidate biomarker verification. Five proteins were selected for initial biomarker verification, including 
CSTB, TPI1, DMBT1, CALML3, and ILIRA. ELISA kits were extensively used for the target protein detection and 
Demographic
Discovery Set Confirmation Set
Cancer (n = 20) Control (n = 20) Cancer (n = 20) Control (n = 20)
Age, years 54.95 ± 10.82 56.10 ± 9.80 54.45 ± 11.14 44.45 ± 12.54
Range 33–76 38–72 30–76 26–67
Sex
 Male 8 8 12 12
 Female 12 12 8 8
Ethnicity
 Korean 20 20 20 20
Smoke History
 Yes 3 3 10 6
Drinking
 Yes 6 5 8 9
H. pylori infection
 Yes 14 5 12 3
Intestinal metaplasia
 Yes 6 5 7 0
T stage
 I, II, III, IV 12, 3, 4, 1 13, 3, 2, 2
Table 1.  Patient Demographics and Clinical Profiles.
Figure 2. Salivary amylase removal by starch affinity column. (A) 1D SDS-PAGE of salivary proteins 
(a) before amylase depletion and (b) after amylase depletion; (B) 2D-DIGE of salivary proteins before amylase 
depletion (a) and after amylase depletion (b); Green: one saliva sample; Red: another saliva sample.
www.nature.com/scientificreports/
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Accession Description # Peptides MW [kDa] pI Ratio (cancer/control)
p value (cancer vs. 
control)
IPI00216984.5 Calmodulin-like protein 3 6 16.9 4.42 0.575 0.008
IPI00021828.1 Cystatin-B 345 11.1 7.56 0.579 0.025
IPI00409567.2 Polycystin-1 3 461.1 6.77 0.584 0.015
IPI00419920.2 carboxylesterase 2 4 67.0 6.57 0.606 0.021
IPI00174541.1 Interleukin-1 receptor antagonist protein 7 16.1 4.88 0.616 0.014
IPI00013384.4 Kinase suppressor of Ras 1 2 96.9 8.57 0.621 0.026
IPI00788666.3 Lipoxygenase homology domain-containing protein 1 4 252.4 5.43 0.633 0.000
IPI00797270.4 Triosephosphate isomerase 39 26.7 6.90 0.640 0.030
IPI00456853.4 WASH complex subunit FAM21C 2 143.6 4.79 0.640 0.031
IPI00619925.2 Centromere-associated protein E 7 301.6 5.57 0.643 0.027
IPI00479345.2 Cancer-associated gene 1 protein 6 74.6 5.99 0.645 0.035
IPI00012505.7 Transmembrane protease serine 13 3 57.1 8.60 0.646 0.025
IPI00018294.3 Zinc finger protein Rlf 46 217.8 6.77 0.651 0.009
IPI00070943.4 Phosphatidylinositol 4-kinase alpha 2 231.2 6.87 0.656 0.000
IPI00001159.11 Translational activator GCN1 2 292.6 7.47 0.656 0.016
IPI00604778.1 Vacuolar protein sorting-associated protein 13C 2 402.8 6.38 0.658 0.045
IPI00218684.3 Short of Autism susceptibility gene 2 protein 15 136.3 9.35 0.659 0.021
IPI00290566.1 T-complex protein 1 subunit alpha 16 60.3 6.11 0.671 0.027
IPI00872278.1 Deleted in malignant brain tumors 1 protein 57 273.3 5.44 0.673 0.004
IPI00413365.3 Zinc finger protein 318 4 251.0 7.20 0.675 0.004
IPI00025753.2 Desmoglein-1 9 113.7 5.03 0.687 0.041
IPI00478657.4 G-rich sequence factor 1 2 53.1 6.19 0.690 0.009
IPI00798373.3 Bardet-Biedl syndrome 4 protein 2 58.2 7.31 0.698 0.024
IPI00298994.6 Talin-1 2 269.6 6.07 0.699 0.003
IPI00972974.1 53 kDa protein 5 52.8 5.48 0.703 0.032
IPI00903081.1 Ras-associating and dilute domain-containing protein 2 117.4 7.09 0.709 0.032
IPI00744872.3 Protein FAM179B 2 189.2 8.50 0.715 0.019
IPI00894030.2 258 kDa protein 4 257.8 8.54 0.716 0.041
IPI00555812.5 Vitamin D-binding protein 2 52.9 5.45 0.718 0.031
IPI00384972.3 MLL1/MLL complex subunit KIAA1267 2 120.9 8.75 0.719 0.002
IPI00795394.3 Dynein heavy chain 9, axonemal 2 503.0 5.91 0.719 0.025
IPI00844048.1 Protein C1orf14 2 60.2 5.31 0.750 0.005
IPI00219168.7 Spectrin beta chain, brain 4 7 416.6 6.67 0.759 0.038
IPI00940245.1 Immunoglobulin heavy chain variant 673 44.8 6.13 0.778 0.038
IPI00386879.1 cDNA FLJ14473 fis 673 53.1 6.86 0.778 0.038
IPI00008173.2 Pleckstrin homology domain-containing family G member 1 2 155.3 6.24 0.788 0.021
IPI00151988.4 Zinc finger protein 532 2 141.6 8.65 0.795 0.026
IPI00647704.1 cDNA FLJ41552 fis 652 53.3 6.52 0.802 0.044
IPI00947235.1 8 kDa protein 67 8.2 8.56 0.836 0.005
IPI00874215.2 cDNA FLJ59298 2 134.1 5.44 0.841 0.015
IPI00759613.3 Titin isoform N2-A 36 3711.3 6.52 0.857 0.038
IPI00735451.4 Immunoglobulin heavy chain 29 12.7 8.27 1.131 0.011
IPI00923519.1 Protein unc-80 homolog 2 337.6 7.06 1.207 0.039
IPI00026089.4 Splicing factor 3B 2 145.7 7.09 1.561 0.021
IPI00219076.1 Signal transducer and activator of transcription 2 3 74.6 7.15 1.733 0.026
IPI00947307.1 cDNA FLJ58075 2 108.8 5.77 1.835 0.006
IPI00909737.1 cDNA FLJ55140 2 55.5 4.84 1.992 0.008
IPI00012024.1 Histatin-1 9 7.0 9.13 3.984 0.044
Table 2.  Top ranked salivary protein biomarker candidates.
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quantification. Three of them were successfully verified in the discovery sample (n = 40) with p < 0.05, including 
CSTB, TPI1 and DMBT1. The dot plot of these biomarkers in the 20 cancer samples and 20 control samples are 
shown in Fig. 7.
Candidate biomarker pre-validation. To further test the utility of these 3 candidates, a new sample set 
was utilized for pre-validation, which consisted of another 20 cancer samples and 20 control samples. The ELISA 
results (Supplementary Figure S1) demonstrated that all of them shown significant difference between gastric 
cancer patients and normal control (p < 0.05). To demonstrate the clinical utility of these salivary proteomic 
biomarker signatures for gastric cancer detection, logistic regression models were built based on different com-
binations of biomarkers. Figure 8A is the corresponding dot plot diagram of the three biomarker combination 
(CSTB, TPI1 and DMBT1) in the 40 pre-validation samples.
Biomarker performance and utility. Receiver operating characteristic (ROC) curve was built to evaluate 
the performance of these pre-validated biomarkers, yielding an area under ROC curve (AUC) value between 0.81 
and 0.92. The combination of all there biomarkers could yield an AUC value of 0.93 with 85% sensitivity and 80% 
specificity (Fig. 8B).
Discussion
Biomarker discovery for gastric cancer detection. In total, we identified and quantified 519 proteins 
through the off-line two dimensional LC-MS/MS method (WCX-RPLC). The most abundant protein in saliva 
was selectively removed by affinity column, which greatly improved the resolution of biomarker discovery. When 
compared with ref. 37, about 20% of our identified proteins have been discovered by other approaches. Among 
these quantified proteins, there were 48 proteins shown significant difference between gastric cancer patients and 
normal subjects. Especially, about one third of these differentially altered proteins are gastric cancer related, either 
biologically or clinically, which demonstrated that human saliva could be a valuable medium for the detection of 
gastric cancer.
Of note it that most of these candidate biomarkers were down regulated in the saliva of gastric cancer patients. 
According to our preliminary work on salivary messenger RNA profiling and salivary microbial analysis from a 
similar saliva sample set, most identified candidates (which can differentiate gastric cancer patients from normal 
Figure 3. The fold change distribution (A) of these quantified proteins between cancer and control group. The 
regulation of discovered proteins (B) in cancer and control groups.
www.nature.com/scientificreports/
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control subjects with p < 0.05) were also down regulated in cancer patients (data not shown). The consistency 
among protein, messenger RNA and microbial shown that there are some systematic changes occurred in human 
body that regulated by remote gastric cancer, which is fulfill the prospective of system biology.
Tumor-secreted exosomes have been found as a key player in determining cancer’s organotropic metastasis44. 
We proposed the role of cancer-derived exosomes in salivary biomarker development for systemic diseases and 
tested it in vitro45 and in vivo46. We found that suppression of exosome biogenesis result in the ablation of discrim-
inatory salivary biomarker development, which might explain why saliva could be used for the detection of distal 
systemic disease, like gastric cancer.
The down-regulation of salivary biomarkers in cancer. Through initial verification in the discovery 
sample set and further confirmed in the pre-validation sample set, three proteins were consistently confirmed by 
ELISA. CSTB is an inhibitor of cathepsin proteases, which are increased in cancer. The protein levels of CSTB 
have been shown to correlate with tumor presence and stages. It has also been identified as a potential serum 
marker in hepatocellular carcinoma47. CSTB is a tissue and urinary biomarker for bladder cancer recurrence and 
disease progression48.
Through functional proteomics analysis, TPI1 has been identified in human gastric cancer cells as an anti-drug 
resistance agent49. It was also significantly regulated by H. Pylori in human gastric epithelial AGS cells7.
DMBT1 is a gene that is located at chromosome 10q 25.3–26.1, a possible tumor suppressor locus indicated by 
refinement of the losses of heterozygosity in various cancers50. The loss of DMBT1 expression may preferentially 
take place in well-differentiated gastric carcinoma. However, an upregulation of DMBT1 expression is more fre-
quently found across all gastric cancer types51.
Human calmodulin-like protein (hCLP), is an epithelial-specific Ca2+-binding protein whose expression is 
strongly down regulated in cancers. Loss of immunoreactivity for human calmodulin-like protein is an early event 
in breast cancer development. The tumor-sensitive calmodulin-like protein is a specific light chain of human 
unconventional myosin X52. We also found that CALML3 down-regulated significantly in gastric cancer patients.
Diagnostic utility of salivary biomarkers. The diagnostic utility of these pre-validated biomarkers 
were evaluated by building the ROC curve and calculate their performance. By combining the three biomarkers 
through logistic regression, the biomarker panel could reach AUC value of 0.93 with 85% sensitivity and 80% 
specificity. The results collectively demonstrated that it is very promising to set up a saliva test for the detection of 
gastric cancer through using these developed biomarkers.
Figure 4. TMT quantification data for six candidate markers (A) CSTB, (B) TPI1, (C) DMBT1, (D) CALML3, 
(E) IGH and (F) IL1RA.
www.nature.com/scientificreports/
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Conclusion
To the authors’ best knowledge, this is the first de novo proteomics biomarker discovery in human saliva for the 
detection of gastric cancer. New approaches and strategies were engaged for gastric cancer biomarker discovery. 
Through two phases biomarker development, 48 proteins were successfully discovered through amylase deple-
tion and high throughput quantitative proteomic technology. ELISA further confirmed the presence of three 
candidates in the cancer saliva. Their performance for the detection of gastric cancer was evaluated, which is very 
encouraging for further definitive validation. Relay on the point of care technology, salivary diagnostic could be 
an ideal alternative way for the early detection and screening of gastric cancer.
Figure 5. The MS/MS spectra of two peptides for CSTB with TMT labeling in group I: (A) CID 
spectrum for VHVGDEDFVHLR; (B) HCD spectrum for VHVGDEDFVHLR; (C) TMT reporter 
spectrum for VHVGDEDFVHLR; m/z = 127.1, 128.1 and 129.1 representing 3 normal samples, 
m/z = 130.1 and 131.1 representing 2 gastric cancer samples; (D) TMT reporter spectrum for peptide 
VFQSLPHENKPLTLSNYQTNK; m/z = 127.1, 128.1 and 129.1 representing 3 normal samples, m/z = 130.1 and 
131.1 representing 2 gastric cancer samples.
www.nature.com/scientificreports/
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Materials and Methods
Patients and samples. Our biomarker development consisted of two phases, including biomarker discov-
ery phase and biomarker pre-validation phase (Fig. 1A). In total, 40 cancer patients and 40 normal control sub-
jects were recruited for this study. All the saliva samples were collected under a protocol approved by institutional 
review board (IRB) of Samsung Medical Center and UCLA. All patients provided written informed consents. The 
methods were carried out in accordance with the approved guidelines. All experimental protocols were approved 
by Samsung Medical Center and UCLA Medical Centre Ethics Committee. Unstimulated saliva samples were 
consistently collected, processed, and stabilized as previously described40,41. All the samples were kept at − 80 °C 
prior to assay. Identified proteomic biomarkers were first verified in the discovery sample set (20 gastric cancer 
samples and 20 healthy control samples) and then pre-validated in another sample set (20 gastric cancer samples 
and 20 healthy control samples).
Sample preparation. Saliva protein concentration was determined by BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL, USA). By taking 300 μg of proteins from each individual sample, every four samples were 
pooled into one sample in cancer group and healthy control group, respectively, thus 5 pool cancer samples and 
5 pool healthy control samples were prepared. All the 10 pooled samples were subjected to potato starch affinity 
column for efficiently removal of alpha amylase as previously described53. Briefly, homemade affinity column 
packed with potato starch (Sigma Aldrich, Saint Louis, USA) was used to trap amylase and the flow through were 
collected for further analysis. Equal amount of protein from each pool sample was then used for the following 
experiment. Two pooled saliva samples were made from all the 10 pooled samples as a GIS for the comparison 
Figure 6. Panther gene ontology pathway analysis of all proteins: (A) GO protein class analysis; (B) GO 
pathway analysis.
www.nature.com/scientificreports/
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between two TMT-6plex experiments. 1D SDS-PAGE and 2D-DIGE were run as previously described41 to test 
the efficiency of amylase removal.
Reduction, alkylation, digestion, and labeling with TMT of the saliva samples. For each TMT-
6plex experiment, 100 μg proteins in each pool saliva sample were dissolved in 45 μL of 200 mM TEAB. The sam-
ple was adjusted to a final volume of 100 uL with ultrapure water. With adding 5 μL 200 mM TCEP, the reaction 
was performed for 1 hour at 55 °C. Then, 5 μL of 375 mM IAA was added, and the mixture were reacted for 30 min 
in the dark at room temperature. 5 μL of freshly prepared trypsin (Promega, WI, USA) at 0.5 μg/uL concentration 
in TEAB (200 mM) was added. The digestion was performed overnight at 37 °C.
In group I, 1 GIS, 3 healthy control samples and two cancer samples were labelled by TMT with reporters at 
m/z = 126.1, 127.1, 128.1, 129.1, 130.1, 131.1, respectively (Fig. 1B). In group II, 1 GIS, the left 3 cancer samples 
and 2 healthy controls samples were labelled by another set of TMT with reporters at m/z = 126.1, 127.1, 128.1, 
129.1, 130.1, 131.1, respectively. After 1 h of reaction at RT, 8 μL of 5% hydroxylamine (w/v) was added in each 
tube and mixed for 15 min. The six samples in each group were pooled into a new tube, respectively, and dried 
for storage at − 80 °C.
Cation exchange fractionation of the pooled TMT-labeled saliva peptides. The pooled 
TMT-labelled saliva peptides were fractionated by cation-exchange chromatography using a flow rate at 0.8 mL/min 
on a 4.6 mm × 250 mm (5 μm, 125 Å) TSK gel CM-2SW column (Tosoh Bioscience, Stuttgart, Germany). The gra-
dient was run as follows: 0–3 min 100% A (10 mM ammonium acetate, 25% acetonitrile, adjusted to pH = 3 with 
HAC), then to 100% B (200 mM ammonium acetate, 25% acetonitrile, adjusted to pH = 3 with HAC) at 15 min. 
As shown in Supplementary Figure S2, fractions were collected every minute and desalted via PepCleanTM C18 
Figure 7. Dot plot for biomarker verification in discovery sample set (n = 40): (A) CSTB; (B) TPI1; (C) DMBT1.
Figure 8. ROC curve and dot plot diagram for the logistic regression model. (A) dot plot diagram was based 
on the ELISA data of the gastric cancer group (n = 20) and healthy control group (n = 20). (B) the logistic 
regression model using 3 biomarkers (CSTB, TPI1 and DMBT1) in the pre-validation sample set results in AUC 
value of 0.93 with 85% sensitivity and 80% specificity (cutoff, 0.3721).
www.nature.com/scientificreports/
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spin columns (Pierce, Rockford, IL, USA). The 12 fractions were dried under vacuum and stored at − 80 °C for 
further LC-MS/MS analysis.
LC-MS/MS analysis. Peptides in each fraction were rehydrated in 2% (v/v) acetonitrile/0.1% (v/v) formic 
acid in water and injected with an autosampler (Eksigent NanoLC-2D, CA, USA). Peptides were first enriched 
on a reverse phase trap column (ProteoPep II, 100 μm × 2.5 cm, C18, 5 μm, 300 Å, New Objective, USA) and then 
eluted to analytical column (Magic C18AQ, 100 μm × 15 cm, 3 μm, 200 Å, Michrom Bioresources, USA). The 
mobile phase consisted of buffer (A) 2% acetonitrile and 0.1% formic acid in water, and buffer (B) 2% water and 
0.1% formic acid in acetonitrile. A flow rate of 250 nL/min was applied for the separation of peptides for 140 mins. 
The gradient run was follows: 0–1 min, 2% B, then to 30% B at 90 min, 80% B at 110 min, and 2% B at 140 min. The 
mass spectrometer voltage was set to 1800 V and the heated capillary was kept at 180 °C. All mass spectra were 
acquired in the positive ionization mode with m/z scan range of 350–2000. The LTQ-Orbitrap XL (Thermo Fisher 
Scientific, San Jose, USA) was operated in a top 6 configuration at 60,000 resolving power (defined by m/Δm50%) 
for a full scan, with enabled charge state screening, monoisotopic precursor selection enabled, and + 1, and 
unassigned charge states rejected. After master scan, three most intense ions were subjected for collision-induced 
dissociation (CID) fragmentation using an isolation window of 3.0, collision energy of 30, default charge state of 
2 and activation time of 30 ms. Fragmentation of three most intense TMT-reporter-labelled ions was achieved 
with HCD fragmentation at 7500 resolving power in the LTQ-Orbitrap using an isolation window of 2, collision 
energy of 40, default charge state of 2 and activation time of 30 ms.
Protein identification and quantification. LC-MS/MS data analysis was performed with Qual Brower 
(v2.0.7) and Proteome Discoverer (v1.3) interfaced SEQUEST (Human IPI database v3.78, 302626 entries). Up 
to two missed cleavage sites were allowed during the database search. Peptides and proteins identification were 
filtered with charge state dependent cross correlation (Xcorr) ≥ 2.0 and peptide rank No. 1 with requiring at 
least two peptides per protein. The filters allowed a 99% confidence level of protein identification with less than 
1% false discovery rate. The Reporter Ions Quantitizer in the Proteome Discoverer was used to quantify the 
TMT reporter ion intensities at 126.13–131.14 m/z. Protein identification and quantification intensity ratios were 
exported to Microsoft Excel software. Reporter ion isotope correction factors were applied by subtracting the 
contribution of reporter ion isotopes to adjacent reporter ion intensities and adding these intensities back to the 
proper channel, after which data were normalized by median intensities for subsequent analyses.
ELISA. The ELISA tests for CSTB, TPI1 and DMBT1 (Antibodies-online, Atlanta, GA, USA) were performed 
according to the manufacturers’ instructions. All saliva samples were diluted 5 times with sample diluents for all 
three proteins.
Data analysis. The Graphpad Prism (Version 5.01) was used for all data analysis. For the number of pro-
teins quantified in the 10 samples, p value was calculated based on t test and p < 0.05 was used as the cut-off for 
significance. The ROC curve and AUC value were constructed by numerical regression of the ROC curve. The 
confirmed gastric cancer related proteins were fitted for logistic regression models. Protein classification was fin-
ished by Panther Classification System (database version 6.1) based on their molecular function, related biological 
process, cellular component, protein class, and related pathway.
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